KCT0008103已完成未知
Phase IV expolaratory study in comparison of efficacy, safety and usability between autologous serum and platelet rich plasma eye drops at 8 weeks after treatment in moderate to severe dry eye syndrome including Sjogren's syndrome
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 18(Year) 至 o Limit（—）
- 性别
- Female
入选标准
- •Moderate to severe dry eye who diagnosed as Sjogren syndrome
排除标准
- •patients who had other systemic diseases, who had received other eye drops, systemic steroid or immunosuppressive treatment within the previous three months, who had undergone ocular surgery within the previous three months
研究者
相似试验
进行中（未招募）
1 期
Study comparing the efficacy and safety of Benzydamine hydrochloride 0,3% oromucosal spray and Benzydamine hydrochloride 3 mg lozenges in patients with acute sore throat.acute sore throatEUCTR2019-003257-29-HUAngelini S.p.A.363
进行中（未招募）
1 期
Study comparing the efficacy and safety of Benzydamine hydrochloride 0,3% oromucosal spray and Benzydamine hydrochloride 3 mg lozenges in patients with acute sore throat.EUCTR2019-003257-29-PLAngelini S.p.A.356
进行中（未招募）
1 期
Study comparing the effects of two different dosage forms (mouth spray and lozenges) of the same medication (benzydamine) in children aged 6-12 years with sore throat.acute sore throatMedDRA version: 23.1Level: LLTClassification code 10041367Term: Sore throatSystem Organ Class: 100000004855EUCTR2022-003285-20-BGAngelini Pharma S.p.A.356
进行中（未招募）
1 期
Study comparing the effects of two different dosage forms (mouth spray and lozenges) of the same medication (benzydamine) in children aged 6-12 years with sore throat.acute sore throatMedDRA version: 23.1Level: LLTClassification code 10041367Term: Sore throatSystem Organ Class: 100000004855EUCTR2022-003285-20-HUAngelini Pharma S.p.A.356
未知
3 期
Comparison of efficacy and safety of paricalcitol injection with maxacalcitol injection in adult Japanese chronic kidney disease subjects receiving hemodialysis with secondary hyperparathyroidismSecondary hyperparathyroidismJPRN-jRCT2080221462Abbott Japan Co., Ltd.252